newsfilter
← Latest News
GlobeNewswire·

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target

KA

SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today it